These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27646748)

  • 1. Molecular testing to differentiate melanoma from benign nevi: The gold standard limitation.
    Bitterman A
    J Am Acad Dermatol; 2016 Oct; 75(4):849-850. PubMed ID: 27646748
    [No Abstract]   [Full Text] [Related]  

  • 2. Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization.
    Hossain D; Qian J; Adupe J; Drewnowska K; Bostwick DG
    Melanoma Res; 2011 Oct; 21(5):426-30. PubMed ID: 21900793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
    Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
    Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical coherence tomography (OCT) features of nevi and melanomas and their association with intraepidermal or dermal involvement: A pilot study.
    Moraes Pinto Blumetti TC; Cohen MP; Gomes EE; Petaccia de Macedo M; Ferreira de Souza Begnami MD; Tavares Guerreiro Fregnani JH; Duprat JP; Pellacani G; Rezze GG
    J Am Acad Dermatol; 2015 Aug; 73(2):315-7. PubMed ID: 26183975
    [No Abstract]   [Full Text] [Related]  

  • 5. Integrating clinical/dermatoscopic findings and fluorescence in situ hybridization in diagnosing melanocytic neoplasms with less than definitive histopathologic features.
    Nardone B; Martini M; Busam K; Marghoob A; West DP; Gerami P
    J Am Acad Dermatol; 2012 Jun; 66(6):917-22. PubMed ID: 21962759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions.
    Zembowicz A; Yang SE; Kafanas A; Lyle SR
    Arch Pathol Lab Med; 2012 Dec; 136(12):1571-9. PubMed ID: 22480223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
    Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):506-10. PubMed ID: 23197006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.
    Gerami P; Wass A; Mafee M; Fang Y; Pulitzer MP; Busam KJ
    Am J Surg Pathol; 2009 Dec; 33(12):1783-8. PubMed ID: 19809275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular testing of borderline cutaneous melanocytic lesions: SNP array is more sensitive and specific than FISH.
    Carter MD; Durham AB; Miedema JR; Harms PW; Chan MP; Patel RM; Lowe L; Fullen DR; Hristov AC; Wang M; Andea AA
    Hum Pathol; 2019 Apr; 86():115-123. PubMed ID: 30576704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotically Active Nevus and Nevoid Melanoma: A Clinicopathological and Molecular Study.
    Mesbah Ardakani N; Singh S; Thomas C; Van Vliet C; Harvey NT; Calonje JE; Wood BA
    Am J Dermatopathol; 2021 Mar; 43(3):182-190. PubMed ID: 32649342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluorescence in-situ hybridization as a diagnostic tool for cutaneous melanoma].
    Su J; Liu J; Zheng J; You J; Ma X; Zhang Y; Zhang J; Liao S
    Zhonghua Bing Li Xue Za Zhi; 2015 Jan; 44(1):37-41. PubMed ID: 25765029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular testing for melanocytic tumors: a practical update.
    Andea AA
    Histopathology; 2022 Jan; 80(1):150-165. PubMed ID: 34958511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rare melanocytes and nevus-cell nevi].
    Frenk E; Mevorah B; Delacrétaz J
    Hautarzt; 1975 Dec; 26(12):619-24. PubMed ID: 1213881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysplastic nevus syndrome.
    Greene MH
    Hosp Pract (Off Ed); 1984 Jan; 19(1):91-103, 107-8. PubMed ID: 6420327
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluorescence in situ hybridization for ambiguous melanocytic tumors.
    Gammon B; Gerami P
    Histol Histopathol; 2012 Dec; 27(12):1539-42. PubMed ID: 23059884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization for distinguishing cellular blue nevi from blue nevus-like melanoma.
    Gammon B; Beilfuss B; Guitart J; Busam KJ; Gerami P
    J Cutan Pathol; 2011 Apr; 38(4):335-41. PubMed ID: 21251038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What dermoscopy tells us about nevogenesis.
    Zalaudek I; Catricalà C; Moscarella E; Argenziano G
    J Dermatol; 2011 Jan; 38(1):16-24. PubMed ID: 21175751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.
    Woltsche N; Schwab C; Deinlein T; Hofmann-Wellenhof R; Zalaudek I
    Expert Rev Anticancer Ther; 2016 May; 16(5):531-41. PubMed ID: 26999650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomelanomas Following Stevens-Johnson Syndrome.
    Ardakani NM; Tiwari SM; Wood BA
    Am J Dermatopathol; 2017 Nov; 39(11):853-856. PubMed ID: 28763334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CASH algorithm for dermoscopy revisited.
    Henning JS; Stein JA; Yeung J; Dusza SW; Marghoob AA; Rabinovitz HS; Polsky D; Kopf AW
    Arch Dermatol; 2008 Apr; 144(4):554-5. PubMed ID: 18427058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.